neoag
Neoantigen × AI
Daily research signal
№32Brief2026-07-06

Phase 1 Trial Tests Personalized Neoantigen Vaccine With Toripalimab

A new Phase 1 trial is launching to test personalized neoantigen vaccines combined with the PD-1 inhibitor toripalimab in resected NSCLC, marking a key clinical validation step for this combination strategy.trial

Concurrently, preclinical data highlights a methodological advance in TIL therapy, where computational modeling and high-throughput screening are used to enrich tumor-infiltrating lymphocytes with specific neoantigen reactivity prior to expansion.PubMed

2new stories
ClinicaltodayNew

Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has registered a Phase 1 study evaluating personalized cancer vaccines alone and in combination with toripalimab for patients with resected non-small cell lung cancer (NSCLC). The trial features dose escalation and expansion phases to assess safety, tolerability, immunogenicity, and preliminary anti-tumor activity. This represents an early-stage clinical test of combining neoantigen-specific vaccination with checkpoint inhibition in a post-surgical setting.

Lung cancer (NSCLC)
clinicaltrials · today · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Also new today01

01
AI / MethodsyesterdayNew

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Preclinical proof-of-concept data demonstrates a SNAP™-TIL platform that combines computational modeling with PepSeq screening to credential and enrich TILs for specific neoantigens. By isolating T cells with high affinity for patient-specific HLA class II proteins before expansion, the platform aims to overcome the rarity of neoantigen-reactive cells in less immunogenic tumors. The approach yielded products with 96% CD3+ content and a mix of effector and central memory subsets, suggesting improved precision in TIL manufacturing.

Peptide vaccines
europepmc · yesterday · Ghosh Halder T, Kelley E, Soria-Bustos J, Thode T, Ng S, Bargenquast T, Weston A, Rodrigue

Explore the field

Field MapTrialsPrimer